menu

Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    There is an unmet clinical need for more durable responses in patients with multiple myeloma because of their inevitable relapses. Advances in our ability to delineate the molecular pathobiology of the disease are guiding impressive new therapeutic options for this patient population. Join Dr. Cesar Rodriguez Valdes and Dr. Amrita Krishnan as they discuss the latest data around emerging agents targeting BCL-2 and BCMA for multiple myeloma and the investigational targets on the horizon.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Amrita Krishnan, MD
    Director of the Judy and Bernard Briskin Center
    City of Hope Comprehensive Cancer Center
    Duarte, CA

    Research: Janssen
    Employee of Ineligible Company: zPREDICTA
    Ownership Interest: Bristol Myers Squibb
    Consulting Fees: Amgen, Bristol Myers Squibb, GlaxoSmithKline, Pfizer, Regeneron, Sanofi, Sutro, Takeda
    Independent Contractor: Janssen

    Cesar Rodriguez Valdes, MD
    Associate Professor of Medicine
    Clinical Director of Multiple Myeloma
    The Mount Sinai Hospital
    New York, NY

    Consulting Fees: Bristol Myers Squibb, Janssen, Sanofi

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Laura Healy has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report. 
    • Brian McDonough, MD has nothing to disclose.
    • Anita Misra-Press, PhD has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize emerging therapeutic strategies to treat patients with relapsed/refractory multiple myeloma
    • Describe the role of current and emerging targets in relapsed/refractory multiple myeloma
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists and hematologist oncologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until June 30, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by independent educational grants from AbbVie, Inc., Bristol Myers Squibb, and Janssen Scientific Affairs, LLC. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    There is an unmet clinical need for more durable responses in patients with multiple myeloma because of their inevitable relapses. Advances in our ability to delineate the molecular pathobiology of the disease are guiding impressive new therapeutic options for this patient population. Join Dr. Cesar Rodriguez Valdes and Dr. Amrita Krishnan as they discuss the latest data around emerging agents targeting BCL-2 and BCMA for multiple myeloma and the investigational targets on the horizon.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Amrita Krishnan, MD
    Director of the Judy and Bernard Briskin Center
    City of Hope Comprehensive Cancer Center
    Duarte, CA

    Research: Janssen
    Employee of Ineligible Company: zPREDICTA
    Ownership Interest: Bristol Myers Squibb
    Consulting Fees: Amgen, Bristol Myers Squibb, GlaxoSmithKline, Pfizer, Regeneron, Sanofi, Sutro, Takeda
    Independent Contractor: Janssen

    Cesar Rodriguez Valdes, MD
    Associate Professor of Medicine
    Clinical Director of Multiple Myeloma
    The Mount Sinai Hospital
    New York, NY

    Consulting Fees: Bristol Myers Squibb, Janssen, Sanofi

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Laura Healy has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report. 
    • Brian McDonough, MD has nothing to disclose.
    • Anita Misra-Press, PhD has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize emerging therapeutic strategies to treat patients with relapsed/refractory multiple myeloma
    • Describe the role of current and emerging targets in relapsed/refractory multiple myeloma
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists and hematologist oncologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until June 30, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by independent educational grants from AbbVie, Inc., Bristol Myers Squibb, and Janssen Scientific Affairs, LLC. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule16 Aug 2022
Webpack App